Skip to content
The Kids Research Institute Australia logo
Donate

Search

Research

Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens

These findings suggest that tumor cells employ multiple epigenetic and genetic mechanisms to evade immune control

Research

Tissue-resident memory T cells orchestrate tumour-immune equilibrium

Our findings provide insight into the immune cell populations important for maintaining long-term tumour dormancy in peripheral tissues

Research

Dendritic cells and cancer: From biology to therapeutic intervention

In this review, we discuss the different subsets of tumor-infiltrating dendritic cells and their role in anti-tumor immunity

Research

CD8+XCR1neg Dendritic Cells Express High Levels of Toll-Like Receptor 5 and a Unique Complement of Endocytic Receptors

Our data demonstrate that CD8+XCR1neg DCs possess a unique pattern of endocytic receptors and a restricted TLR profile that is particularly enriched for TLR5

Research

Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin

Our results show that TRM cells have a fundamental role in the surveillance of subclinical melanomas in the skin by maintaining cancer-immune equilibrium

Research

PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein

Our findings present a novel mouse model for glioma demonstrating that the PI3K pathway is important for initiation of tumorigenesis

Research

Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors

Early changes in cell morphology upon treatments are a strong indication that the inhibitor is directly targeting tubulin

Research

Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3

These findings implicate the activation of STAT3 as one pathway that may mediate resistance to IGF-II-targeted therapy in HCC

Research

Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients

All children who are receiving therapy for cancer should receive a single dose of PCV13 as soon as possible after diagnosis, regardless of prior PCV exposure.